2019. 1. 14. - Leerink Partners rated the Clovis Oncology, Inc. (NASDAQ:CLVS)'s stock as an Outperform in a research note published on Tuesday, . 2019. 2. 4. - Clovis Oncology, Inc. (NASDAQ:CLVS) stock enjoyed an overall . The 1.54% rally might have been tempting for an investor to buy at this point . 2019. 3. 4. - The -0.96% drop in Clovis Oncology, Inc. (NASDAQ:CLVS) might have been tempting for an investor to sell at this point but in fact that would . 2018. 8. 8. - It has been a tough 2018 so far for PARP concerns like Clovis Oncology and Tesaro. Clovis reported second-quarter results last week, which . 2019. 1. 7. - Shares of Clovis Oncology (NASDAQ:CLVS) soared over 21% today after the company announced product revenue for the fourth quarter and . 2017. 12. 29. - Mid-caps stocks, like Clovis Oncology Inc (NASDAQ:CLVS) with a market capitalization of .29B, aren't the focus of most investors who prefer . Clovis Oncology to Present at the Barclays Global Healthcare Conference What an incredible run it has been thus far, and I'm really tempted to sell and cash . 2019. 2. 18. - Clovis Oncology, Inc. (NASDAQ:CLVS) has had quite a year when it comes to price Investors should be tempted to take a look at this stock:. Clovis' product development programs generally target specific subsets of cancer, and the Company seeks to simultaneously develop, with partners, diagnostic . 2015. 7. 9. - Clovis Oncology will sell 75 million in stock to raise funds for cancer drug But, by far, the most tempting part of doing business in the state .